Waisman has in‐depth experience in manufacturing a wide range of biologics for human clinical trials including gene therapeutics, cell therapeutics, and vaccines. Waisman has developed platform manufacturing processes and analytical methods to support clinical production of several classes of biologics including plasmid DNA, Mesenchymal Stromal Cells (MSCs), human Embryonic Stem Cells (hESCs), adenoviral/adeno‐associated viral vectors, and recombinant proteins. In addition, Waisman has supported the development and clinical production of a number of novel types of biologics from process development through to aseptic fill and finish. With a broad range of experience in product development and clinical production, Waisman has the insight and expertise to identify and address key issues as we work with you to produce your clinical trial material.
Waisman seeks to improve the efficiency of developing new classes of drugs, such as stem cells, in order to get treatments to patients more quickly and at a lower cost.
For more information about Waisman Biomanufacturing services, please contact:
Room T411 | 608-262-9618